Loss of presenilin 2 age-dependently alters susceptibility to acute seizures and kindling acquisition.
Aging
Alzheimer's
Carbamazepine
Corneal kindling
Diazepam
Epilepsy
Lamotrigine
Levetiracetam
Presenilin
Seizures
Valproic acid
Journal
Neurobiology of disease
ISSN: 1095-953X
Titre abrégé: Neurobiol Dis
Pays: United States
ID NLM: 9500169
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
14
08
2019
revised:
17
11
2019
accepted:
16
12
2019
pubmed:
22
12
2019
medline:
5
1
2021
entrez:
22
12
2019
Statut:
ppublish
Résumé
Patients with Alzheimer's disease (AD) experience seizures at higher rates than the general population of that age, suggesting an underexplored role of hyperexcitability in AD. Genetic variants in presenilin (PSEN) 1 and 2 genes lead to autosomal dominant early-onset AD (ADAD); patients with PSEN gene variants also report seizures. Pharmacological control of seizures in AD may be disease-modifying. Preclinical efficacy of FDA-approved antiseizure drugs (ASDs) is well defined in young adult rodents; however, the efficacy of ASDs in aged rodents with chronic seizures is less clear. The mechanism by which ADAD genes lead to AD remains unclear, and even less studied is the pathogenesis of epilepsy in AD. PSEN variants generally all result in a biochemical loss of function (De Strooper, 2007). We herein determined whether well-established models of acute and chronic seizure could be used to explore the relationship between AD genes and seizures through investigating whether loss of normal PSEN2 function age-dependently influenced susceptibility to seizures and/or corneal kindling acquisition. PSEN2 knockout (KO) and age-matched wild-type (WT) mice were screened from 2- to 10-months-old to establish age-dependent focal seizure threshold. Additionally, PSEN2 KO and WT mice aged 2- and 8-months-old underwent corneal kindling such that mice were aged 3- and 9-months old at the beginning of ASD efficacy testing. We then defined the dose-dependent efficacy of mechanistically distinct ASDs on kindled seizures of young versus aged mice to better understand the applicability of corneal kindling to real-world use for geriatric patients. PSEN2 KO mice demonstrated early-life reductions in seizure threshold. However, kindling acquisition was delayed in 2-month-old PSEN2 KO versus WT mice. Young male WT mice took 24.3 ± 1.3 (S.E.M.) stimulations to achieve kindling criterion, whereas age-matched PSEN2 KO male mice took 41.2 ± 1.1 stimulations (p < .0001). The rate of kindling acquisition of 8-month-old mice was no longer different from WT. This study demonstrates that loss of normal PSEN2 function is associated with age-dependent changes in the in vivo susceptibility to acute seizures and kindling. Loss of normal PSEN2 function may be an underexplored molecular contributor to seizures. The use of validated models of chronic seizures in aged rodents may uncover age-related changes in susceptibility to epileptogenesis and/or ASD efficacy in mice with AD-associated genotypes, which may benefit the management of seizures in AD.
Identifiants
pubmed: 31862541
pii: S0969-9961(19)30394-8
doi: 10.1016/j.nbd.2019.104719
pmc: PMC7462087
mid: NIHMS1622056
pii:
doi:
Substances chimiques
Presenilin-2
0
Psen2 protein, mouse
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
104719Subventions
Organisme : NCATS NIH HHS
ID : KL2 TR000421
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR002317
Pays : United States
Informations de copyright
Copyright © 2019. Published by Elsevier Inc.
Références
Arch Neurol. 2009 Apr;66(4):435-40
pubmed: 19204149
Epilepsia Open. 2018 Sep 15;3(Suppl Suppl 1):53-68
pubmed: 30450485
Exp Neurol. 2013 Dec;250:143-50
pubmed: 24029002
Epilepsia. 2018 Oct;59(10):1931-1944
pubmed: 30194729
Nat Med. 2017 Jun;23(6):678-680
pubmed: 28459436
Epilepsia. 2016 Sep;57(9):1386-97
pubmed: 27466022
Epilepsy Behav. 2004 Dec;5(6):866-72
pubmed: 15582834
J Biol Chem. 2004 Nov 5;279(45):46907-14
pubmed: 15345711
Epilepsy Res. 1998 Jun;31(1):59-71
pubmed: 9696301
Epilepsy Res. 2010 Dec;92(2-3):163-9
pubmed: 20951004
EMBO Rep. 2007 Feb;8(2):141-6
pubmed: 17268505
J Pharmacol Exp Ther. 1985 Mar;232(3):741-5
pubmed: 3919174
J Biol Chem. 2016 Jun 10;291(24):12821-37
pubmed: 27059953
Epilepsia. 2018 Jan;59(1):67-78
pubmed: 29152735
Epilepsia. 2004 Sep;45(9):1009-16
pubmed: 15329063
Neurobiol Aging. 2017 Feb;50:64-76
pubmed: 27889678
Brain Struct Funct. 2010 Mar;214(2-3):127-43
pubmed: 19921519
J Neurosci. 2011 Jan 12;31(2):700-11
pubmed: 21228179
Curr Alzheimer Res. 2016;13(7):817-30
pubmed: 26825094
Epilepsia. 2007 Oct;48(10):1861-9
pubmed: 17521346
Psychopharmacologia. 1963 Jul 2;4:343-53
pubmed: 14048555
Nat Rev Neurosci. 2015 Jun;16(6):358-72
pubmed: 25991443
Neurochem Res. 2017 Jul;42(7):1904-1918
pubmed: 28303498
Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):11872-7
pubmed: 10518543
Epilepsia. 2009 Jul;50(7):1752-9
pubmed: 19453707
Epilepsy Curr. 2010 Jan;10(1):15-20
pubmed: 20126334
Brain. 2010 Apr;133(Pt 4):1143-54
pubmed: 20375137
Expert Opin Drug Discov. 2019 Oct;14(10):947-951
pubmed: 31248287
Epilepsia. 2013 Aug;54 Suppl 4:44-60
pubmed: 23909853
Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):E2895-903
pubmed: 22869752
Neurobiol Dis. 2010 Oct;40(1):303-10
pubmed: 20600912
J Physiol. 2008 Jul 15;586(14):3405-23
pubmed: 18483067
J Pharmacol Exp Ther. 1953 Jun;108(2):168-76
pubmed: 13062087
Curr Opin Neurol. 2014 Apr;27(2):199-205
pubmed: 24553459
Neuron. 2007 Sep 6;55(5):697-711
pubmed: 17785178
Adv Neurol. 1986;44:921-34
pubmed: 3518352
Epilepsia. 2010 Jul;51 Suppl 3:34-8
pubmed: 20618397
Neuropharmacology. 2013 Jun;69:16-24
pubmed: 22521336
Epilepsy Behav. 2017 Apr;69:186-222
pubmed: 28237319
Mol Neurobiol. 2015 Aug;52(1):545-54
pubmed: 25204494
Neurology. 2016 Aug 30;87(9):912-9
pubmed: 27466472
Ann Neurol. 1989 Mar;25(3):213-20
pubmed: 2471436
J Alzheimers Dis. 2016 Apr 18;52(3):1125-33
pubmed: 27104892
Neurology. 1951 Nov-Dec;1(6):444-60
pubmed: 14899586
Epilepsia. 1986 Jan-Feb;27(1):19-26
pubmed: 3081335
J Neurosci. 2015 Apr 15;35(15):6221-30
pubmed: 25878292
Cell. 2012 Apr 27;149(3):708-21
pubmed: 22541439
Epilepsia. 2006 Jul;47(7):1094-120
pubmed: 16886973
Receptors Clin Investig. 2015;2(1):e449
pubmed: 25646163
Epilepsy Res. 2015 May;112:43-55
pubmed: 25847338
J Neuropathol Exp Neurol. 2016 Apr;75(4):366-78
pubmed: 26945036
J Neurochem. 2005 Jan;92(2):294-301
pubmed: 15663477
J Neurosci. 1996 Dec 1;16(23):7513-25
pubmed: 8922407
Epilepsia. 2006 May;47(5):867-72
pubmed: 16686651
Epilepsy Res. 2018 Feb;140:90-94
pubmed: 29310076
JAMA Neurol. 2013 Sep 1;70(9):1158-66
pubmed: 23835471
Epilepsia. 2018 Jun;59(6):1245-1256
pubmed: 29750337
Epilepsia. 2010 Mar;51(3):454-64
pubmed: 19845729
Brain. 2016 Sep;139(Pt 9):2441-55
pubmed: 27497924
Epilepsy Res. 2001 Dec;47(3):217-27
pubmed: 11738929
Epilepsy Res. 2011 Mar;94(1-2):75-85
pubmed: 21300523
Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9861-6
pubmed: 15210974
Electroencephalogr Clin Neurophysiol. 1972 Mar;32(3):281-94
pubmed: 4110397
Proc Natl Acad Sci U S A. 2013 Sep 10;110(37):15091-6
pubmed: 23918386
Brain. 1992 Aug;115 ( Pt 4):1001-15
pubmed: 1393499
J Neurochem. 1998 Jul;71(1):313-22
pubmed: 9648880
J Alzheimers Dis. 2010;22(2):393-9
pubmed: 20847431
PLoS One. 2010 Dec 29;5(12):e15743
pubmed: 21206757
J Physiol. 2010 Jul 15;588(Pt 14):2517
pubmed: 20634179
Oncotarget. 2017 Oct 16;8(59):99284-99295
pubmed: 29245901
Lancet Neurol. 2017 Apr;16(4):311-322
pubmed: 28327340
Adv Exp Med Biol. 2014;813:295-308
pubmed: 25012386
J Nucl Med. 1989 Oct;30(10):1607-15
pubmed: 2795200
Epilepsia. 2017 Jul;58 Suppl 3:39-47
pubmed: 28675559
J Neurochem. 2013 Dec;127(5):592-9
pubmed: 23952003
Neurobiol Dis. 2017 Sep;105:221-234
pubmed: 28624414